Researchers at Queen Mary University of London’s Precision Healthcare Research Institute (PHURI) and the Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin have identified the genetic causes of Raynaud’s phenomenon. Their findings, published today (12 October) in Nature Communications, could lead to the first effective treatments for people with Raynaud’s.
J&J builds out global manufacturing capacity for CAR-T Carvykti
Johnson & Johnson is ramping up manufacturing capacity for the CAR-T therapy it developed with Legend Biotech, driven by high demand for the Carvykti, executives